Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)

References

• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi: 10.1159/000370220.
   PubMed Web of Science ®Google Scholar
• Grant L, Seiding Larsen L, Trennery C, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30(4):247–254. doi: 10.1097/DER.0000000000000486.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Lei D, Yousaf M, et al. Comparison of Patient-Oriented Eczema Measure and Patient-Oriented Scoring Atopic Dermatitis vs. Eczema Area and Severity Index and other measures of atopic dermatitis: a validation study. Ann Allergy Asthma Immunol. 2020;125(1):78–83. doi: 10.1016/j.anai.2020.03.006.
   PubMed Web of Science ®Google Scholar
• Thomas KS, Apfelbacher CA, Chalmers JR, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol. 2021;185(1):139–146. doi: 10.1111/bjd.19751.
   PubMed Web of Science ®Google Scholar
• Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79. doi: 10.1111/bjd.14773.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, et al. Patient-reported outcome measures: use in medical product development to support labeling claims. Food and Drug Administration; 2009 [cited 2021 Oct 30]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
   Google Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity - establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-Eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–977. doi: 10.1016/j.jval.2011.06.014.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity – establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-Assessing respondent understanding. Value Health. 2011;14(8):978–988. doi: 10.1016/j.jval.2011.06.013.
   PubMed Web of Science ®Google Scholar
• Foley C, Tundia N, Simpson E, et al. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019;35(7):1139–1148. doi: 10.1080/03007995.2018.1560222.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, McLafferty M, et al. Content validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in adolescents to assess the symptoms and impacts of atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis (RAD) Congress, 2020 Dec 13-14, 2020, Virtual.
   Google Scholar
• Silverberg JI, Simpson EL, Litcher-Kelly L, et al. Psychometric evaluation of three patient-reported outcome questionnaires assessing the symptoms and impacts of atopic dermatitis in adults and adolescents. Presented at the Revolutionizing Atopic Dermatitis (RAD) Congress, 2020 Dec 13-14, 2020, Virtual.
   Google Scholar
• Silverberg JI, Simpson E, Calimlim BM, et al. Determining severity strata for three atopic dermatitis patient-reported outcome questionnaires: defining severity score ranges for the Worst Pruritus numerical rating scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther. 2022;12(12):2817–2827. doi: 10.1007/s13555-022-00836-5.
   Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/S0140-6736(21)00589-4.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi: 10.1111/j.0022-202X.2005.23621.x.
   PubMed Web of Science ®Google Scholar
• Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22. doi: 10.1002/hec.3564.
   PubMed Web of Science ®Google Scholar
• University of Nottingham Centre of Evidence Based Dermatology. POEM – Patient Oriented Eczema Measure; 2021 [cited 2021 Nov 12]. Available from: https://www.nottingham.ac.uk/research/groups/cebd/resources/poem.aspx.
   Google Scholar
• Oakley A. EASI Score. DermNet New Zealand: 01/2015; 2015 [cited 2019 Sep 8]. Available from: http://www.dermnetnz.org/topics/easi-score/.
   Google Scholar
• Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–18. doi: 10.1034/j.1600-0625.2001.100102.x.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846. doi: 10.1016/j.jaad.2020.04.104.
   PubMed Web of Science ®Google Scholar
• European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology. 1993;186:23–31.
   PubMed Web of Science ®Google Scholar
• Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on atopic dermatitis. Dermatology. 1997;195(1):10–19. doi: 10.1159/000245677.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, McLafferty M, et al. Content validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in adolescents to assess the symptoms and impacts of atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis (RAD) Congress, 2020 Dec 13-14, Virtual.
   Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769. doi: 10.1111/bjd.17744.
   PubMed Web of Science ®Google Scholar
• Schnitzler C, Rosen J, Szepietowski J, et al. Validation of ‘ItchApp©’ in Poland and in the USA: multicentre validation study of an electronical diary for the assessment of pruritus. J Eur Acad Dermatol Venereol. 2019;33(2):398–404. doi: 10.1111/jdv.15300.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–507. doi: 10.2340/00015555-1246.
   PubMed Web of Science ®Google Scholar